$KRYS
Krystal Biotech, Inc.

2020 Q1 Form 10-K Financial Statement

#000156459020009550 Filed on March 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2018 Q4 2018
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.420M $1.420M $4.160M
YoY Change 58.17% 246.34% 166.67%
% of Gross Profit
Research & Development $3.525M $2.800M $7.761M
YoY Change 11.3% 156.88% 141.93%
% of Gross Profit
Depreciation & Amortization $335.0K $60.00K $141.0K
YoY Change 153.79% 500.0% 513.04%
% of Gross Profit
Operating Expenses $5.946M $4.220M $7.761M
YoY Change 87.75% 181.33% 62.64%
Operating Profit -$5.946M -$11.92M
YoY Change 149.71%
Interest Expense $0.00 $510.0K $1.030M
YoY Change -100.0% 363.64% -132.7%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.340M -$3.710M -$10.89M
YoY Change 29.93% 166.91% 37.5%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.341M -$3.710M -$10.89M
YoY Change 29.92% 166.91% 37.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$307.6K -$273.4K -$972.3K
COMMON SHARES
Basic Shares Outstanding 17.36M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $186.7M $111.8M $111.8M
YoY Change 75.14% 125.32% 125.4%
Cash & Equivalents $180.2M $103.7M $103.7M
Short-Term Investments $6.500M $8.091M $8.100M
Other Short-Term Assets $1.600M $900.0K $900.0K
YoY Change 23.08% 4636.84% 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $188.3M $112.7M $112.7M
YoY Change 74.51% 125.69% 125.85%
LONG-TERM ASSETS
Property, Plant & Equipment $12.90M $3.014M $3.000M
YoY Change 74.32% 1407.0% 1400.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $3.900M $452.0K $500.0K
YoY Change 757.14%
Total Long-Term Assets $16.80M $3.466M $3.400M
YoY Change 115.27% 1633.0% 1600.0%
TOTAL ASSETS
Total Short-Term Assets $188.3M $112.7M $112.7M
Total Long-Term Assets $16.80M $3.466M $3.400M
Total Assets $205.1M $116.1M $116.1M
YoY Change 77.26% 131.7% 131.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $888.0K $900.0K
YoY Change -46.71% 360.1% 350.0%
Accrued Expenses $3.200M $1.500M $1.500M
YoY Change 52.38% 275.0% 400.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.100M $2.596M $2.600M
YoY Change 26.47% 305.63% 333.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.700M $294.0K $300.0K
YoY Change -10.0%
Total Long-Term Liabilities $2.700M $294.0K $300.0K
YoY Change -10.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.100M $2.596M $2.600M
Total Long-Term Liabilities $2.700M $294.0K $300.0K
Total Liabilities $6.800M $2.890M $2.900M
YoY Change 9.36% 351.56% 383.33%
SHAREHOLDERS EQUITY
Retained Earnings -$19.96M
YoY Change 120.06%
Common Stock $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $198.4M $113.2M $113.2M
YoY Change
Total Liabilities & Shareholders Equity $205.1M $116.1M $116.1M
YoY Change 77.26% 131.7% 131.74%

Cashflow Statement

Concept 2020 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$5.341M -$3.710M -$10.89M
YoY Change 29.92% 166.91% 37.5%
Depreciation, Depletion And Amortization $335.0K $60.00K $141.0K
YoY Change 153.79% 500.0% 513.04%
Cash From Operating Activities -$6.227M -$3.520M -$9.445M
YoY Change 93.69% 65.26% 142.8%
INVESTING ACTIVITIES
Capital Expenditures $1.508M -$1.300M $2.234M
YoY Change -11.66% 712.5% 963.81%
Acquisitions
YoY Change
Other Investing Activities $200.0K -$2.460M -$8.090M
YoY Change -125.64%
Cash From Investing Activities -$1.305M -$3.760M -$10.32M
YoY Change -47.42% 2250.0% 4815.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $243.0K $73.85M
YoY Change 507.5% 73.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $243.0K 64.29M 73.85M
YoY Change 507.5% -9417.39% 42.64%
NET CHANGE
Cash From Operating Activities -$6.227M -3.520M -9.445M
Cash From Investing Activities -$1.305M -3.760M -10.32M
Cash From Financing Activities $243.0K 64.29M 73.85M
Net Change In Cash -$7.289M 57.01M 54.08M
YoY Change 28.85% -2013.09% 13.44%
FREE CASH FLOW
Cash From Operating Activities -$6.227M -$3.520M -$9.445M
Capital Expenditures $1.508M -$1.300M $2.234M
Free Cash Flow -$7.735M -$2.220M -$11.68M
YoY Change 57.15% 12.69% 184.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14428916
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Registrant Name
EntityRegistrantName
Krystal Biotech, Inc.
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001711279
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Security12b Title
Security12bTitle
Common Stock
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Trading Symbol
TradingSymbol
KRYS
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17357935
CY2019Q2 dei Entity Public Float
EntityPublicFloat
454000000
CY2019 dei Entity File Number
EntityFileNumber
001-38210
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1080209
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Wharton Street
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 701
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Pittsburgh
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15203
CY2019 dei City Area Code
CityAreaCode
412
CY2019 dei Local Phone Number
LocalPhoneNumber
586-5830
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
187514000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
133183000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2018Q4 us-gaap Liabilities
Liabilities
2890000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Liabilities
Liabilities
6109000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
241951000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
724000
CY2018Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1708000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3327000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2596000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39047000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19959000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
202914000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
113226000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
209023000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116116000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1462000
CY2019Q4 us-gaap Assets
Assets
209023000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14428916
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15616000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7761000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17354310
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-22081000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-11916000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73847000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19080000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10887000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15901083
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11203081
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
792000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103670000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
6171000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
8091000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2195000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
889000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
195880000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
112650000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8475000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3014000
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
497000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2709000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
452000
CY2018Q4 us-gaap Assets
Assets
116116000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
888000
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
2123000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
480000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2782000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
294000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17354310
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
49474000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
107529000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1239000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
399515
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9325000
CY2019Q4 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
991000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
72000
CY2019Q4 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
510000
CY2019Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
40000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19000
CY2019Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2123000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
721000
CY2019 us-gaap Depreciation
Depreciation
748000
CY2018 us-gaap Depreciation
Depreciation
141000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1239000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
792000
CY2019 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-67000
CY2019 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
226000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
891000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
321000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-199000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
112000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
547000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
644000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1362000
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
76000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18713000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9445000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6399000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2234000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
8573000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
8089000
CY2019 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
10501000
CY2019 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
497000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4968000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10323000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
107525000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
73847000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
107525000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73847000
CY2019 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
83844000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
54079000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49591000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
681000
CY2018Q4 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
348000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: stock-based compensation expense, accrued research and development expenses, the fair value of financial instruments, incremental borrowing rate for lease liability, and the valuation allowance included in deferred income taxes calculations.</p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and&#160;Off-Balance&#160;Sheet Risk</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company&#8217;s policy is to invest its cash and cash equivalents in money market funds, certificate of deposits and various bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.&#160;The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with&#160;off-balance&#160;sheet risk of loss.</p>
CY2018Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
154000
CY2019Q4 krys Accrued Construction In Progress And Laboratory Equipment
AccruedConstructionInProgressAndLaboratoryEquipment
491000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
193700000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 krys Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
420766
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2019Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
194172000
CY2019Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
194182000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2018Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
111759000
CY2018Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
111761000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3180000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
850000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
166000
CY2018Q4 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
537000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
41000
CY2018Q4 krys Accrued Construction In Progress And Laboratory Equipment
AccruedConstructionInProgressAndLaboratoryEquipment
589000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
39000
CY2018Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1708000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.96
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.73
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1244000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.04
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.08
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
20.82
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.71
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.52
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2020Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2027-02-28
CY2019 krys Lease Termination Date
LeaseTerminationDate
2035-10-31
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3029000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1358000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1385000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1413000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1441000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
11317000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19943000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
195500
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4243
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
19500
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
357089
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
159500
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
72073
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
23750
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
420766
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
109390
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.79
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.46
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4302000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15859000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5236000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3777000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
545824
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4008000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2287000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6471000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2296000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1522000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-913000
CY2019 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
-110000
CY2018 us-gaap Income Tax Reconciliation Prior Year Income Taxes
IncomeTaxReconciliationPriorYearIncomeTaxes
852000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 krys Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
785000
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
261000
CY2018Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
102000
CY2019Q4 krys Deferred Tax Liabilities Unrealized Loss On Marketable Securities
DeferredTaxLiabilitiesUnrealizedLossOnMarketableSecurities
3000
CY2018Q4 krys Deferred Tax Liabilities Unrealized Loss On Marketable Securities
DeferredTaxLiabilitiesUnrealizedLossOnMarketableSecurities
1000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1052000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
145000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
604000
CY2018 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
143000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-223000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
189000
CY2019 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
-4000
CY2018 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
6000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9934000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4262000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
140000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
77000
CY2019Q4 krys Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
945000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
144000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
123000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
820000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
143000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
11983000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4605000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10931000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4460000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1052000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
145000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
3000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
42000
CY2019 krys Ownership Interest Rate Change Over Period
OwnershipInterestRateChangeOverPeriod
P3Y

Files In Submission

Name View Source Status
0001564590-20-009550-index-headers.html Edgar Link pending
0001564590-20-009550-index.html Edgar Link pending
0001564590-20-009550.txt Edgar Link pending
0001564590-20-009550-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g04hpahoeeew000001.jpg Edgar Link pending
g04hpahoeeew000002.jpg Edgar Link pending
gclrjxb1p1bp000001.jpg Edgar Link pending
gclrjxb1p1bp000002.jpg Edgar Link pending
ge25uc3ruoul000001.jpg Edgar Link pending
ge25uc3ruoul000002.jpg Edgar Link pending
gokigbquvya2000001.jpg Edgar Link pending
gokigbquvya2000002.jpg Edgar Link pending
gzyq455r24cn000001.jpg Edgar Link pending
gzyq455r24cn000002.jpg Edgar Link pending
gzyq455r24cn000003.jpg Edgar Link pending
gzyq455r24cn000004.jpg Edgar Link pending
krys-10k_20191231.htm Edgar Link pending
krys-20191231.xml Edgar Link completed
krys-20191231.xsd Edgar Link pending
krys-20191231_cal.xml Edgar Link unprocessable
krys-20191231_def.xml Edgar Link unprocessable
krys-20191231_lab.xml Edgar Link unprocessable
krys-20191231_pre.xml Edgar Link unprocessable
krys-ex1013_80.htm Edgar Link pending
krys-ex1014_79.htm Edgar Link pending
krys-ex1015_81.htm Edgar Link pending
krys-ex1016_82.htm Edgar Link pending
krys-ex211_78.htm Edgar Link pending
krys-ex231_8.htm Edgar Link pending
krys-ex311_9.htm Edgar Link pending
krys-ex312_11.htm Edgar Link pending
krys-ex321_7.htm Edgar Link pending
krys-ex322_10.htm Edgar Link pending
krys-ex43_128.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending